Pharmaceuticals

MEDLEY Opens Philippines Office to Support Global Growth

MANILA, Philippines, April 4, 2024 /PRNewswire/ -- Medley, Inc. (TSE: 4480) ("MEDLEY"), aJapan-based internet service company, opened its Philippine office in Bonifacio Global City (BGC), Taguig onApril 1st to support continued global growth. The opening of the new office and upcoming operation l...

2024-04-04 10:59 4952

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-03 20:00 3082

Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan

BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March inBishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai C...

2024-04-03 16:16 4640

Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024

SINGAPORE, April 3, 2024 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announcedSingapore's top 10 Best Workplaces in Healthcare and Biopharma™  in 2024.

2024-04-03 12:00 5907

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its inno...

2024-04-03 11:14 3260

Latvian pharmaceutical manufacturing company Grindeks opens new subsidiaries worldwide

RIGA, Latvia, April 3, 2024 /PRNewswire/ -- The leading pharmaceutical company in the Baltics, Grindeks, is developing new products and reinforcing its position not only in European but also global markets. With determination and innovative approaches, Grindeks continues to enhance the competitiv...

2024-04-03 05:00 3245

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

TAMPA, Fla., April 2, 2024 /PRNewswire/ -- Concept Medical has been granted 'IDE Approval' from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, to initiate a clinical study for the treatment of stenotic lesions of Arteriovenous Fis...

2024-04-02 17:33 4544

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune,...

2024-04-02 13:00 4269

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

HONG KONG and SHANGHAI, April 2, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended31 December 2023 (the "Reporting Period"). During the R...

2024-04-02 11:31 5139

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights

SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2023 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2023, Alphamab Onc...

2024-03-29 10:42 9815

Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future

Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative position compared to the corresponding period of las...

2024-03-28 22:46 9517

Sirnaomics Announces 2023 Annual Results

Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; st...

2024-03-28 17:09 7153

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

ST. GALLEN, SWITZERLAND, March 28, 2024 /PRNewswire/ -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adul...

2024-03-28 15:00 2279

TCI Gene Enhancing Malaysia's Preventive Healthcare In Collaboration With ALPRO Pharmacy

TAIPEI, March 28, 2024 /PRNewswire/ -- TCI Gene announced a strategic partnership with Alpro Pharmacy, a renowned chain pharmacy leader inMalaysia, to exclusively offer its genetic assessment services to Malaysians. TCI Gene and Alpro Pharmacy aims to provide Malaysians with better preventive hea...

2024-03-28 12:30 3404

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

BEIJING and HONG KONG, March 28, 2024 /PRNewswire/ -- XtalPi, a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, today announced it will present a poster showcasing the latest a...

2024-03-28 09:05 3743

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023

SHANGHAI, March 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for ...

2024-03-28 07:01 7166

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * Healthy financial position with cash reserves of RMB 1,026.7 million as of December 31, 2023 and net loss narrowed by 57% from the past year * CStone established strategic collaborations with multip...

2024-03-27 22:00 5540

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...

2024-03-27 08:00 3631

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release of the report "A White Paper To Understand The Market Structure Of Pediatric Pertussis Hexavalent and Combination Vaccines

2024-03-26 21:00 1838

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 2531
1 ... 81828384858687 ... 184